[Translation] A multicenter, randomized, controlled clinical trial comparing the efficacy and safety of sipuleucel-T with abiraterone acetate or enzalutamide in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
主要目的:
与醋酸阿比特龙或恩杂鲁胺对比,评价sipuleucel-T治疗中国无症状或轻微症状的mCRPC患者的总生存期(OS)以及生存风险比(HR)与已有研究结果的一致性。
次要目的:
与醋酸阿比特龙或恩杂鲁胺对比,评价 sipuleucel-T在中国无症状或轻微症状的mCRPC患者中的安全性。
[Translation] Primary objective:
Compared with abiraterone acetate or enzalutamide, evaluate the consistency of overall survival (OS) and survival hazard ratio (HR) of sipuleucel-T in the treatment of Chinese patients with asymptomatic or mild symptoms of mCRPC with existing research results.
Secondary objective:
Compared with abiraterone acetate or enzalutamide, evaluate the safety of sipuleucel-T in Chinese patients with asymptomatic or mild symptoms of mCRPC.